Pharsight

1. Absorica Ld patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711	SUN PHARM	Low dose oral pharmaceutical composition of isotretinoin	May, 2035 (11 years from now)
US9700535	SUN PHARM	Oral pharmaceutical composition of isotretinoin	Aug, 2035 (11 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Market Authorisation Date: 05 November, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
8MG	CAPSULE;ORAL	Prescription
16MG	CAPSULE;ORAL	Prescription
20MG	CAPSULE;ORAL	Discontinued
24MG	CAPSULE;ORAL	Prescription
28MG	CAPSULE;ORAL	Discontinued
32MG	CAPSULE;ORAL	Prescription

ABSORICA LD family patents

2. Accrufer patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP15784705A	2018-09-05	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9802973	SHIELD TX	Crystalline forms of ferric maltol	Oct, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179120	SHIELD TX	Dosage regimen of ferric trimaltol	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 2023-07-26

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
30MG IRON	CAPSULE;ORAL	Prescription

ACCRUFER family patents

3. Adhansia Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500162	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10512612	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10292938	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US9974752	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10292939	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10512613	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10688060	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10449159	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10507186	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10568841	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)
US10111839	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
35MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
45MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
55MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
70MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
85MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

ADHANSIA XR family patents

4. Adrenalin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130592	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)
US9119876	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)
US9295657	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL ampules	09 Mar, 2016	1	06 Jul, 2018	13 Mar, 2035	Deferred
30 mg/30 mL	20 Aug, 2018	1	24 Apr, 2020	13 Mar, 2035	Eligible

Strength	Dosage	Availability
EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	Prescription

ADRENALIN family patents

5. Airduo Digihaler patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP19155324A	2021-06-29	Vectura Limited	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957 (Pediatric)	TEVA PHARM	Dry powder inhaler	Apr, 2035 (11 years from now)
US9415008 (Pediatric)	TEVA PHARM	Dry powder inhaler	Apr, 2035 (11 years from now)
US9782551	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US9782550	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US10918816	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

AIRDUO DIGIHALER family patents

6. Akynzeo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10676440	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (11 years from now)
US10961195	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (11 years from now)
US9951016	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (11 years from now)
US10233154	HELSINN HLTHCARE	Crystalline forms of an NK-1 antagonist	Sep, 2035 (11 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
300MG;EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

AKYNZEO family patents

7. Alecensa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350214	HOFFMANN-LA ROCHE	Preparation containing tetracyclic compound at high dose	Apr, 2035 (11 years from now)
US11433076	HOFFMANN-LA ROCHE	Preparation containing tetracyclic compound at high dose	Apr, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg	11 Dec, 2019	1		04 Mar, 2032

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

ALECENSA family patents

8. Alunbrig patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385078	TAKEDA PHARMS USA	Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine	Nov, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 22, 2027
New Indication (I)	May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

ALUNBRIG family patents

9. Amvuttra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11401517	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (11 years from now)
US10612024	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 13, 2027
Orphan Drug Exclusivity (ODE)	Jun 13, 2029

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: 2026-06-13

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
25MG/0.5ML (25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

AMVUTTRA family patents

10. Aponvie patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744800	HERON THERAPS INC	Methods of use of emulsion formulations of an NK-1 receptor antagonist	Sep, 2035 (11 years from now)
US10500208	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974793	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974742	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US11173118	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US9561229	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9808465	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974794	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10624850	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US10953018	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method for preventing of post-operative nausea and vomiting; A method of administering aprepitant for prevention of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

Strength	Dosage	Availability
32MG/4.4ML (7.2MG/ML)	EMULSION;INTRAVENOUS	Prescription

APONVIE family patents

11. Arakoda patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744828	60 DEGREES PHARMS	Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects	Dec, 2035 (12 years from now)
US10342791	60 DEGREES PHARMS	Regimens of tafenoquine for prevention of malaria in malaria-naive subjects	Dec, 2035 (12 years from now)
US10888558	60 DEGREES PHARMS	Regimens of tafenoquine for prevention of malaria in malaria-naive subjects	Dec, 2035 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 20, 2023

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: 2022-07-20

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription

ARAKODA family patents

12. Arikayce Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10251900	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (11 years from now)
US10751355	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (11 years from now)
US9895385	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (11 years from now)
US11446318	INSMED INC	Methods for treating pulmonary non-tuberculous mycobacterial infections	May, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN)	Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part o...

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

Strength	Dosage	Availability
EQ 590MG BASE/8.4ML	SUSPENSION, LIPOSOMAL;INHALATION	Prescription

ARIKAYCE KIT family patents

13. Aristada patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10813928	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (11 years from now)
US9452131	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (11 years from now)
US10238651	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (11 years from now)
US11406632	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (11 years from now)
US9526726	ALKERMES INC	Aripiprazole formulations having increased injection speeds	Mar, 2035 (11 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

ARISTADA family patents

14. Aristada Initio Kit patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP15750750A	2019-11-27	Generics (UK) Ltd	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849894	ALKERMES INC	Aripiprazole prodrug composition	Aug, 2035 (11 years from now)
US11154552	ALKERMES INC	Aripiprazole prodrug composition	Aug, 2035 (11 years from now)
US10688091	ALKERMES INC	Aripiprazole prodrug composition	Aug, 2035 (11 years from now)
US10016415	ALKERMES INC	Aripiprazole prodrug compositions	Sep, 2035 (11 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
675MG/2.4ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

ARISTADA INITIO KIT family patents

15. Armonair Digihaler patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP19155324A	2021-06-29	Vectura Limited	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US9782550	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US10918816	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Jul 9, 2024
New Strength (NS)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

ARMONAIR DIGIHALER family patents

16. Axumin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933147	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)
US10716868	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)
US10124079	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)
US10967077	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
9-221mCi/ML	SOLUTION;INTRAVENOUS	Prescription

AXUMIN family patents

17. Bafiertam patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566259	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (11 years from now)
US10098863	BANNER LIFE SCIENCES	Fumarate esters	Feb, 2035 (11 years from now)
US9820961	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (11 years from now)
US10105336	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (11 years from now)
US9814691	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (11 years from now)
US9636318	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (11 years from now)
US9814692	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (11 years from now)
US10105335	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (11 years from now)
US9511043	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (11 years from now)
US9326965	BANNER LIFE SCIENCES	Controlled release fumarate esters	Feb, 2035 (11 years from now)
US9517209	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (11 years from now)
US9820960	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (11 years from now)
US9326947	BANNER LIFE SCIENCES	Controlled release fumarate esters	Feb, 2035 (11 years from now)
US10105337	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Feb, 2035 (11 years from now)
US9636319	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Feb, 2035 (11 years from now)
US10918616	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Jun, 2035 (11 years from now)
US10918617	BANNER LIFE SCIENCES	Fumarate ester pharmaceutical compositions	Aug, 2035 (11 years from now)
US10918615	BANNER LIFE SCIENCES	Fumarate esters	Aug, 2035 (11 years from now)
US10945985	BANNER LIFE SCIENCES	Fumarate ester dosage forms	Aug, 2035 (11 years from now)

Drugs and Companies using MONOMETHYL FUMARATE ingredient

Market Authorisation Date: 28 April, 2020

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
95MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

BAFIERTAM family patents

18. Balversa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9902714	JANSSEN BIOTECH	Quinoxaline derivatives useful as FGFR kinase modulators	Mar, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

BALVERSA family patents

19. Biktarvy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708342	GILEAD SCIENCES INC	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate	Jun, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10385067	GILEAD SCIENCES INC	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate	Jun, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 7, 2023
Orphan Drug Exclusivity (ODE)	Oct 7, 2028
M (M)	Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 2022-02-07

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

BIKTARVY family patents

20. Brexafemme patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10927142	SCYNEXIS	Salts and polymorphs of SCY-078	Jan, 2035 (11 years from now)
US10174074	SCYNEXIS	Salts and polymorphs of SCY-078	Jan, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406	SCYNEXIS	Salts and polymorphs of SCY-078	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 1, 2026
New Indication (I)	Nov 30, 2025
Generating Antibiotic Incentives Now (GAIN)	Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 2030-06-01

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

BREXAFEMME family patents

21. Bunavail patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522188	BDSI	Abuse resistant transmucosal drug delivery device	Apr, 2035 (11 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

BUNAVAIL family patents

22. Calquence patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083	ASTRAZENECA	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	Jan, 2035 (11 years from now)
US11771696	ASTRAZENECA	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocy...

Dosage: CAPSULE;ORAL

CALQUENCE family patents

23. Calquence patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083	ASTRAZENECA	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	Jan, 2035 (11 years from now)
US11771696	ASTRAZENECA	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 2021-10-31

Market Authorisation Date: 03 August, 2022

Dosage: TABLET;ORAL

CALQUENCE family patents

24. Cinvanti patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744800	HERON THERAPS INC	Methods of use of emulsion formulations of an NK-1 receptor antagonist	Sep, 2035 (11 years from now)
US10624850	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US9808465	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10953018	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974794	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974742	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US10500208	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974793	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US11173118	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US9561229	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

CINVANTI family patents

25. Cyclophosphamide patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662342	EUGIA PHARMA SPECLTS	Formulations of cyclophosphamide liquid concentrate	Jun, 2035 (11 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 25 August, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE family patents

26. Cyclophosphamide patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849916	DR REDDYS	Stable liquid formulations of cyclophosphamide and its impurities	Jul, 2035 (11 years from now)
US11382923	DR REDDYS	Stable liquid formulations of cyclophosphamide and processes to prepare the same	Dec, 2035 (12 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 07 June, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE family patents

27. Dayvigo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652	EISAI INC	Compositions and methods for treating insomnia	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 7, 2025
M (M)	Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 2024-04-07

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

DAYVIGO family patents

28. Definity patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10022460	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (12 years from now)
US11395856	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (12 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (12 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

DEFINITY family patents

29. Epidiolex patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11096905	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Oct, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956185	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956184	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10709674	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10603288	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11633369	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10137095	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10111840	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956183	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10092525	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9956186	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US9949937	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10709671	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11701330	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11357741	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11311498	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11446258	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11154516	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10709673	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10966939	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US10849860	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11766411	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2035 (11 years from now)
US11400055	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (11 years from now)
US11065209	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (11 years from now)
US10918608	GW RES LTD	Use of cannabidiol in the treatment of epilepsy	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 28, 2023
Orphan Drug Exclusivity (ODE)	Jul 31, 2027
New Patient Population (NPP)	Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: 2022-09-28

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of convulsive seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatmen...

Dosage: SOLUTION;ORAL

EPIDIOLEX family patents

30. Ermeza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772	MYLAN	Liquid levothyroxine formulations	Feb, 2035 (11 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 29 April, 2022

Treatment: NA

Dosage: SOLUTION;ORAL

ERMEZA family patents

31. Eskata patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098910	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (11 years from now)
US10729720	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (11 years from now)
US10493103	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (11 years from now)
US9980983	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (11 years from now)
US9675639	ACLARIS	Peroxide formulations and methods and applicators for using the same	Jul, 2035 (11 years from now)

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Market Authorisation Date: 14 December, 2017

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION;TOPICAL

ESKATA family patents

32. Evrysdi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9969754	GENENTECH INC	Compounds for treating spinal muscular atrophy	May, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 27, 2029
New Chemical Entity Exclusivity (NCE)	Aug 7, 2025
New Patient Population (NPP)	May 27, 2025
M (M)	Oct 3, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 2024-08-07

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

EVRYSDI family patents

33. Evzio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Mar, 2035 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO family patents

34. Evzio (autoinjector) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Mar, 2035 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO (AUTOINJECTOR) family patents

35. Exem Foam Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259494	GISKIT	Composition and method for medical imaging of body cavities	May, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 2023-11-08

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

EXEM FOAM KIT family patents

36. Exkivity patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227342	TAKEDA PHARMS USA	Heteroaryl compounds for kinase inhibition	May, 2035 (11 years from now)
US9796712	TAKEDA PHARMS USA	Heteroaryl compounds for kinase inhibition	May, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 15, 2026
Orphan Drug Exclusivity (ODE)	Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: 2025-09-15

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE;ORAL

EXKIVITY family patents

37. Fetroja patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10004750	SHIONOGI INC	Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof	Sep, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982	SHIONOGI INC	Preparation containing cephalosporin having a catechol moiety	Sep, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 14, 2024
New Indication (I)	Sep 25, 2023
Generating Antibiotic Incentives Now (GAIN)	Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 2028-11-14

Market Authorisation Date: 14 November, 2019

Treatment: NA

Dosage: POWDER;INTRAVENOUS

FETROJA family patents

38. Fintepla patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331	ZOGENIX INC	Control system for control of distribution of medication	Sep, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 25, 2029
New Product (NP)	Jun 25, 2023
New Indication (I)	Mar 25, 2025
Pediatric Exclusivity (PED)	Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution

Dosage: SOLUTION;ORAL

FINTEPLA family patents

39. Firvanq Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959948	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)
US11638692	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)
US10959947	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)
US10959949	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)
US10959946	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)
US10688046	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)
US10493028	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (11 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

FIRVANQ KIT family patents

40. Genosyl patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737051	VERO BIOTECH	Nitrogen dioxide storage device	Oct, 2035 (11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

GENOSYL family patents

41. Hetlioz patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11760740	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
US10829465	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
US11566011	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
US10071977	VANDA PHARMS INC	Highly purifid pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487	VANDA PHARMS INC	Method of treatment	Jul, 2035 (11 years from now)
US11266622	VANDA PHARMS INC	Method of treatment	Aug, 2035 (11 years from now)
US10179119	VANDA PHARMS INC	Method of treatment	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication (I)	Dec 1, 2023
Orphan Drug Exclusivity (ODE)	Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration...

Dosage: CAPSULE;ORAL

HETLIOZ family patents

42. Hetlioz Lq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10071977	VANDA PHARMS INC	Highly purifid pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
US11760740	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
US10829465	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
US11566011	VANDA PHARMS INC	Highly purified pharmaceutical grade tasimelteon	Feb, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487	VANDA PHARMS INC	Method of treatment	Jul, 2035 (11 years from now)
US10179119	VANDA PHARMS INC	Method of treatment	Aug, 2035 (11 years from now)
US11266622	VANDA PHARMS INC	Method of treatment	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Dec 1, 2023
Orphan Drug Exclusivity (ODE)	Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by admi...

Dosage: SUSPENSION;ORAL

HETLIOZ LQ family patents

43. Illuccix patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031	TELIX	Kit for radiolabelling	Jul, 2035 (11 years from now)

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 17 December, 2021

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

ILLUCCIX family patents

44. Imbruvica patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9795604 (Pediatric)	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Apr, 2035 (11 years from now)
US10463668 (Pediatric)	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Apr, 2035 (11 years from now)
US10695350 (Pediatric)	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Apr, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 24, 2029
ODE* (ODE*)	Aug 2, 2024
New Patient Population (NPP)	Aug 24, 2025
Pediatric Exclusivity (PED)	Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

IMBRUVICA family patents

45. Impoyz patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855334	PRIMUS PHARMS	Topical compositions comprising a corticosteroid	Mar, 2035 (11 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: NA

Dosage: CREAM;TOPICAL

IMPOYZ family patents

46. Inlyta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202	PF PRISM CV	Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer	Feb, 2035 (11 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

INLYTA family patents

47. Isturisa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143680	RECORDATI RARE	Pharmaceutical dosage forms	Jul, 2035 (11 years from now)
US10709691	RECORDATI RARE	Pharmaceutical dosage forms	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 6, 2025
Orphan Drug Exclusivity (ODE)	Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

ISTURISA family patents

48. Jublia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601	BAUSCH	Applicator	Apr, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

JUBLIA family patents

49. Jylamvo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129833	THERAKIND	Methotrexate formulation	Oct, 2035 (11 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 29 November, 2022

Treatment: NA

Dosage: SOLUTION;ORAL

JYLAMVO family patents

50. Kapspargo Sprinkle patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504655	SPIL	Capsule dosage form of metoprolol succinate	Jul, 2035 (11 years from now)
US9700530	SPIL	Capsule dosage form of metoprolol succinate	Jul, 2035 (11 years from now)

Drugs and Companies using METOPROLOL SUCCINATE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE family patents

51. Kengreal patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295687	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (11 years from now)
US10039780	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (11 years from now)
US9439921	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (11 years from now)
US9700575	CHIESI	Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same	Jul, 2035 (11 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous inf...

Dosage: POWDER;INTRAVENOUS

KENGREAL family patents

52. Kimyrsa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9649352	MELINTA THERAP	High purity oritavancin and method of producing same	Jul, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Mar 12, 2024
New Chemical Entity Exclusivity (NCE)	Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN)	Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 12 March, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

KIMYRSA family patents

53. Lenvima patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10407393	EISAI INC	High-purity quinoline derivative and method for manufacturing same	Aug, 2035 (11 years from now)
US11186547	EISAI INC	High-purity quinoline derivative and method for manufacturing same	Aug, 2035 (11 years from now)
US10259791	EISAI INC	High-purity quinoline derivative and method for manufacturing same	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 15, 2025
M (M)	Dec 19, 2024
New Indication (I)	Aug 10, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

LENVIMA family patents

54. Licart patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351133	IBSA INST BIO	Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug	Feb, 2035 (11 years from now)
US11344520	IBSA INST BIO	Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug	Feb, 2035 (11 years from now)

Drugs and Companies using DICLOFENAC EPOLAMINE ingredient

Market Authorisation Date: 19 December, 2018

Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released

Dosage: SYSTEM;TOPICAL

LICART family patents

55. Lodoco patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265281	AGEPHA PHARMA FZ	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative	Jan, 2035 (11 years from now)
US10842762	AGEPHA PHARMA FZ	Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent	Jan, 2035 (11 years from now)
US11026899	AGEPHA PHARMA FZ	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative	Jan, 2035 (11 years from now)
US11026900	AGEPHA PHARMA FZ	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative	Jan, 2035 (11 years from now)
US9744144	AGEPHA PHARMA FZ	Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent	Jan, 2035 (11 years from now)
US10206891	AGEPHA PHARMA FZ	Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent	Jan, 2035 (11 years from now)
US11026901	AGEPHA PHARMA FZ	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative	Jan, 2035 (11 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 16 June, 2023

Treatment: A method for treating and/or reducing the risk of a cardiovascular event; A method of treating and/or reducing the risk of inflammation, atherosclerotic vascular disease, and cholesterol crystal induc...

Dosage: TABLET;ORAL

LODOCO family patents

56. Lokelma patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9592253	ASTRAZENECA	Extended use zirconium silicate compositions and methods of use thereof	Oct, 2035 (11 years from now)
US10300087	ASTRAZENECA	Extended use zirconium silicate compositions and methods of use thereof	Oct, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11738044	ASTRAZENECA	Extended use zirconium silicate compositions and methods of use thereof	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 18, 2023
M (M)	Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 2022-05-18

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

LOKELMA family patents

57. Lonhala Magnair Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376661	SUNOVION RESP	Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element	Sep, 2035 (11 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

LONHALA MAGNAIR KIT family patents

58. Mavyret patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48923	ABBVIE INC	Crystal forms	May, 2035 (11 years from now)
US9321807	ABBVIE INC	Crystal forms	Jun, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48923 (Pediatric)	ABBVIE INC	Crystal forms	Nov, 2035 (11 years from now)
US9321807 (Pediatric)	ABBVIE INC	Crystal forms	Dec, 2035 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Apr 10, 2023
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
Pediatric Exclusivity (PED)	Dec 10, 2028

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS;ORAL

MAVYRET family patents

59. Narcan patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211253	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US10085937	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US9561177	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US9629965	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US9468747	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US9707226	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US9775838	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)
US9480644	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 November, 2015

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED;NASAL

NARCAN family patents

60. Nityr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029	CYCLE PHARMS LTD	Pharmaceutical composition	Jan, 2035 (11 years from now)

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 26 July, 2017

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

NITYR family patents

61. Obredon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10105324	SOVEREIGN PHARMS	Immediate release oral guaifenesin solution	Nov, 2035 (11 years from now)
US9549907	SOVEREIGN PHARMS	Immediate release oral guaifenesin solution	Nov, 2035 (11 years from now)
US9808431	SOVEREIGN PHARMS	Immediate release oral guaifenesin solution	Nov, 2035 (11 years from now)

Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 14 November, 2014

Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or i...

Dosage: SOLUTION;ORAL

OBREDON family patents

62. Ojjaara patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48285	GLAXOSMITHKLINE	N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide	Jun, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9809559	GLAXOSMITHKLINE	(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide	Jun, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 15, 2030
New Chemical Entity Exclusivity (NCE)	Sep 15, 2028

Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-09-16

Market Authorisation Date: 15 September, 2023

Treatment: For the treatment of intermediate or high-risk myelofibrosis

Dosage: TABLET;ORAL

OJJAARA family patents

63. Omlonti patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10774072	SANTEN	Crystal of N-substituted sulfonamide compound	Jun, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415038	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US11197849	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10179127	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10765750	SANTEN	Pharmaceutical composition containing pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
USRE48183	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10702511	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

OMLONTI family patents

64. Ongentys patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357468	NEUROCRINE	Medicaments for slowing Parkinson's disease	May, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 2024-04-24

Market Authorisation Date: 24 April, 2020

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

ONGENTYS family patents

65. Onpattro patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11079379	ALNYLAM PHARMS INC	Methods of treating transthyretin (TTR) mediated amyloidosis	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 10, 2025
New Chemical Entity Exclusivity (NCE)	Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

ONPATTRO family patents

66. Opfolda patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10208299	AMICUS THERAP US	Highly potent acid alpha-glucosidase with enhanced carbohydrates	Sep, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10961522	AMICUS THERAP US	Highly potent acid alpha-glucosidase with enhanced carbohydrates	Sep, 2035 (11 years from now)
US11753632	AMICUS THERAP US	Highly potent acid alpha-glucosidase with enhanced carbohydrates	Sep, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE;ORAL

OPFOLDA family patents

67. Orbactiv patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649352	MELINTA THERAP	High purity oritavancin and method of producing same	Jul, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN)	Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 06 August, 2014

Treatment: NA

Dosage: POWDER;INTRAVENOUS

ORBACTIV family patents

68. Orladeyo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10329260	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)
US10125102	BIOCRYST	Human plasma kallikrein inhibitors	Apr, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)
US11230530	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)
US11708333	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 3, 2027
New Chemical Entity Exclusivity (NCE)	Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 2024-12-03

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and ped...

Dosage: CAPSULE;ORAL

ORLADEYO family patents

69. Otiprio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220796	ALK ABELLO	Sterilization of ciprofloxacin composition	Jul, 2035 (11 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: NA

Dosage: INJECTABLE, SUSPENSION;OTIC

OTIPRIO family patents

70. Oxbryta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447071	GLOBAL BLOOD THERAPS	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	Feb, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722502	GLOBAL BLOOD THERAPS	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	Feb, 2035 (11 years from now)
US11452720	GLOBAL BLOOD THERAPS	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	Feb, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 25, 2024
Orphan Drug Exclusivity (ODE)	Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 2023-11-26

Market Authorisation Date: 17 December, 2021

Treatment: Treating sickle cell disease by administering voxelotor and another active agent

Dosage: TABLET, FOR SUSPENSION;ORAL

OXBRYTA family patents

71. Oxlumo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10612024	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (11 years from now)
US11401517	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (11 years from now)
US10612027	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (11 years from now)
US11446380	ALNYLAM PHARMS INC	Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression	Oct, 2035 (11 years from now)
US10478500	ALNYLAM PHARMS INC	Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Oct 6, 2029
New Chemical Entity Exclusivity (NCE)	Nov 23, 2025
New Indication (I)	Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 2024-11-23

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

OXLUMO family patents

72. Pemazyre patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9611267	INCYTE CORP	Substituted tricyclic compounds as FGFR inhibitors	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 17, 2025
Orphan Drug Exclusivity (ODE)	Aug 26, 2029
New Indication (I)	Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: NA

Dosage: TABLET;ORAL

PEMAZYRE family patents

73. Pemetrexed patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11147817	SHILPA	Pharmaceutical composition of pemetrexed	Mar, 2035 (11 years from now)

Drugs and Companies using PEMETREXED DISODIUM ingredient

Market Authorisation Date: 22 May, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

PEMETREXED family patents

74. Pemfexy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604990	EAGLE PHARMS	Crystalline forms of pemetrexed diacid and manufacturing processes therefor	Oct, 2035 (11 years from now)

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

PEMFEXY family patents

75. Ponvory patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220023	JANSSEN PHARMS	Dosing regimen for a selective S1P1 receptor agonist	Dec, 2035 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...

Dosage: TABLET;ORAL

PONVORY family patents

76. Proair Digihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US9782550	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US10918816	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (12 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

PROAIR DIGIHALER family patents

77. Qalsody patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10385341	BIOGEN MA	Compositions for modulating SOD-1 expression	Apr, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10669546	BIOGEN MA	Compositions for modulating SOD-1 expression	Apr, 2035 (11 years from now)
US10968453	BIOGEN MA	Compositions for modulating SOD-1 expression	Apr, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 25, 2030
New Chemical Entity Exclusivity (NCE)	Apr 25, 2028

Drugs and Companies using TOFERSEN ingredient

NCE-1 date: 2027-04-26

Market Authorisation Date: 25 April, 2023

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene

Dosage: SOLUTION;INTRATHECAL

QALSODY family patents

78. Qbrelis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814751	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US11771733	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10940177	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US11179434	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US9463183	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10265370	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10406199	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US10039800	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)
US9616096	AZURITY	Lisinopril formulations	Nov, 2035 (11 years from now)

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Treatment of myocardial infarction; Method of treating hypertension; Treatment of heart failure; Method of treatment of heart failure; Reduction of mortality in acute myocardial infarction; Treatment ...

Dosage: SOLUTION;ORAL

QBRELIS family patents

79. Qulipta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836	ABBVIE INC	Tablet formulation for CGRP active compounds	Jan, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication (I)	Apr 17, 2026
New Chemical Entity Exclusivity (NCE)	Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 2025-09-28

Market Authorisation Date: 28 September, 2021

Treatment: NA

Dosage: TABLET;ORAL

QULIPTA family patents

80. Rezlidhia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9834539	RIGEL PHARMS INC	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors	Sep, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10550098	RIGEL PHARMS INC	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors	Sep, 2035 (11 years from now)
US10414752	RIGEL PHARMS INC	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors	Sep, 2035 (11 years from now)
US11498913	RIGEL PHARMS INC	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors	Sep, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 1, 2027
Orphan Drug Exclusivity (ODE)	Dec 1, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 2026-12-01

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating a cancer where the cancer is acute myeloid leukemia (aml)

Dosage: CAPSULE;ORAL

REZLIDHIA family patents

81. Rezurock patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311541	KADMON PHARMS LLC	Treatment of GVHD	Apr, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 16, 2026
Orphan Drug Exclusivity (ODE)	Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 2025-07-16

Market Authorisation Date: 16 July, 2021

Treatment: Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy

Dosage: TABLET;ORAL

REZUROCK family patents

82. Rhofade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517560	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (11 years from now)
US10335391	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (11 years from now)
US10751325	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (11 years from now)
US9974773	EPI HLTH	Stabilized oxymetazoline formulations and their uses	Jun, 2035 (11 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: Once daily topical treatment of persistent facial erythema associated with rosacea in female adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1...

Dosage: CREAM;TOPICAL

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9522188	December, 2012	Decision	Andrew Finn et al

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10272083	February, 2023	Institution Denied	Acerta Pharma B.V. et al.	Sandoz Inc.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10272083	February, 2023	Institution Denied	Acerta Pharma B.V. et al.	Sandoz Inc.

Strength	Dosage	Availability
EQ 30MG BASE;120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.1 mg/0.3 mg and 4.2 mg/0.7 mg	23 Nov, 2016	1		20 Aug, 2032
6.3 mg/1 mg	21 Dec, 2015	1		20 Aug, 2032

Strength	Dosage	Availability
EQ 2.1MG BASE;EQ 0.3MG BASE	FILM;BUCCAL	Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE	FILM;BUCCAL	Discontinued
EQ 6.3MG BASE;EQ 1MG BASE	FILM;BUCCAL	Discontinued

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg/2.5 mL and 1 g/5 mL	07 Mar, 2022	1		15 Feb, 2036
2 g/10 mL	17 Jan, 2023	1		15 Feb, 2036

Strength	Dosage	Availability
1GM/5ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/2.5ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
1GM/2ML (500MG/ML)	SOLUTION;INTRAVENOUS	Prescription
2GM/4ML (500MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/ML (500MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP15784111A	2021-04-29	James Poole Limited	Granted and Under Opposition

Application	Filing Date	Opposition Party	Legal Status

EP15813093A	2022-07-13	Elkington and Fife LLP	Granted and Under Opposition

Strength	Dosage	Availability
EQ 25MG BASE/ML	FOR SOLUTION;ORAL	Prescription
EQ 50MG BASE/ML	FOR SOLUTION;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
70 mg	14 Dec, 2018	1	31 Mar, 2021	30 Oct, 2033	Eligible
140 mg	13 Nov, 2017	8	31 Mar, 2021	24 Oct, 2034	Deferred
140 mg and 560 mg	05 Nov, 2018	1		03 Mar, 2036
280 mg and 420 mg	14 Dec, 2018	1		03 Mar, 2036

Strength	Dosage	Availability
140MG	TABLET;ORAL	Prescription
280MG	TABLET;ORAL	Prescription
420MG	TABLET;ORAL	Prescription
560MG	TABLET;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP18205542A	2022-06-01	König Szynka Tilmann von Renesse	Granted and Under Opposition
EP18205542A	2022-05-31	Pohlman, Sandra M.	Granted and Under Opposition
EP18205542A	2022-05-31	Pajaro Limited	Granted and Under Opposition
EP18205542A	2022-05-27	Boult Wade Tennant LLP	Granted and Under Opposition
EP18205542A	2022-05-26	Symbiosis IP Limited	Granted and Under Opposition
EP18205542A	2022-05-20	Hoffmann Eitle	Granted and Under Opposition
EP18205542A	2022-05-13	Wuesthoff & Wuesthoff Patentanwälte PartG mbB	Granted and Under Opposition
EP15703439A	2019-08-14	König Szynka Tilmann von Renesse	Granted and Under Opposition
EP15703439A	2019-08-14	Withers & Rogers LLP	Granted and Under Opposition

Strength	Dosage	Availability
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 25MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 50MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG TARTRATE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP19151846A	2023-05-10	Generics (U.K.) Limited	Granted and Under Opposition
EP19151846A	2023-05-10	Aechter, Bernd	Granted and Under Opposition
EP19151846A	2023-05-10	Maiwald GmbH	Granted and Under Opposition
EP19151846A	2023-05-10	Accord Healthcare	Granted and Under Opposition
EP19151846A	2023-05-10	Welding GmbH & Co. KG	Granted and Under Opposition
EP19151846A	2023-05-10	STADA Arzneimittel AG	Granted and Under Opposition
EP19151846A	2023-05-09	Hansen, Norbert	Granted and Under Opposition
EP19151846A	2023-05-09	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP19151846A	2023-05-04	ELKINGTON AND FIFE LLP	Granted and Under Opposition

Strength	Dosage	Availability
EQ 4MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
5GM/PACKET	FOR SUSPENSION;ORAL	Prescription
10GM/PACKET	FOR SUSPENSION;ORAL	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9561177	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9629965	February, 2019	Final Written Decision	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9468747	February, 2019	Final Written Decision	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9468747	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9211253	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9775838	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9211253	February, 2019	Final Written Decision	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9629965	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/spray	28 Dec, 2017	1		16 Mar, 2035
4 mg/spray	15 Jul, 2016	1	19 Apr, 2019	16 Mar, 2035	Eligible

Strength	Dosage	Availability
2MG/SPRAY	SPRAY, METERED;NASAL	Discontinued
4MG/SPRAY	SPRAY, METERED;NASAL	Prescription

Pharsight

Drug Patents Expiring in 2035

1. Absorica Ld patents expiration Share with your colleague

ABSORICA LD family patents

2. Accrufer patents expiration Share with your colleague

ACCRUFER family patents

3. Adhansia Xr patents expiration Share with your colleague

ADHANSIA XR family patents

4. Adrenalin patents expiration Share with your colleague

ADRENALIN family patents

5. Airduo Digihaler patents expiration Share with your colleague

AIRDUO DIGIHALER family patents

6. Akynzeo patents expiration Share with your colleague

AKYNZEO family patents

7. Alecensa patents expiration Share with your colleague

ALECENSA family patents

8. Alunbrig patents expiration Share with your colleague

ALUNBRIG family patents

9. Amvuttra patents expiration Share with your colleague

AMVUTTRA family patents

10. Aponvie patents expiration Share with your colleague

APONVIE family patents

11. Arakoda patents expiration Share with your colleague

ARAKODA family patents

12. Arikayce Kit patents expiration Share with your colleague

ARIKAYCE KIT family patents

13. Aristada patents expiration Share with your colleague

ARISTADA family patents

14. Aristada Initio Kit patents expiration Share with your colleague

ARISTADA INITIO KIT family patents

15. Armonair Digihaler patents expiration Share with your colleague

ARMONAIR DIGIHALER family patents

16. Axumin patents expiration Share with your colleague

AXUMIN family patents

17. Bafiertam patents expiration Share with your colleague

BAFIERTAM family patents

18. Balversa patents expiration Share with your colleague

BALVERSA family patents

19. Biktarvy patents expiration Share with your colleague

BIKTARVY family patents

20. Brexafemme patents expiration Share with your colleague

BREXAFEMME family patents

21. Bunavail patents expiration Share with your colleague

BUNAVAIL family patents

22. Calquence patents expiration Share with your colleague

CALQUENCE family patents

23. Calquence patents expiration Share with your colleague

CALQUENCE family patents

24. Cinvanti patents expiration Share with your colleague

CINVANTI family patents

25. Cyclophosphamide patents expiration Share with your colleague

CYCLOPHOSPHAMIDE family patents

26. Cyclophosphamide patents expiration Share with your colleague

CYCLOPHOSPHAMIDE family patents

27. Dayvigo patents expiration Share with your colleague

DAYVIGO family patents

28. Definity patents expiration Share with your colleague

DEFINITY family patents

29. Epidiolex patents expiration Share with your colleague

EPIDIOLEX family patents

30. Ermeza patents expiration Share with your colleague

ERMEZA family patents

31. Eskata patents expiration Share with your colleague

ESKATA family patents

32. Evrysdi patents expiration Share with your colleague

EVRYSDI family patents

33. Evzio patents expiration Share with your colleague

EVZIO family patents

34. Evzio (autoinjector) patents expiration Share with your colleague

EVZIO (AUTOINJECTOR) family patents

35. Exem Foam Kit patents expiration Share with your colleague

EXEM FOAM KIT family patents

36. Exkivity patents expiration Share with your colleague

EXKIVITY family patents

37. Fetroja patents expiration Share with your colleague

FETROJA family patents

38. Fintepla patents expiration Share with your colleague

FINTEPLA family patents

39. Firvanq Kit patents expiration Share with your colleague

FIRVANQ KIT family patents

1. Absorica Ld patents expiration

2. Accrufer patents expiration

3. Adhansia Xr patents expiration

4. Adrenalin patents expiration

5. Airduo Digihaler patents expiration

6. Akynzeo patents expiration

7. Alecensa patents expiration

8. Alunbrig patents expiration

9. Amvuttra patents expiration

10. Aponvie patents expiration

11. Arakoda patents expiration

12. Arikayce Kit patents expiration

13. Aristada patents expiration

14. Aristada Initio Kit patents expiration

15. Armonair Digihaler patents expiration

16. Axumin patents expiration

17. Bafiertam patents expiration

18. Balversa patents expiration

19. Biktarvy patents expiration

20. Brexafemme patents expiration

21. Bunavail patents expiration

22. Calquence patents expiration

23. Calquence patents expiration

24. Cinvanti patents expiration

25. Cyclophosphamide patents expiration

26. Cyclophosphamide patents expiration

27. Dayvigo patents expiration

28. Definity patents expiration

29. Epidiolex patents expiration

30. Ermeza patents expiration

31. Eskata patents expiration

32. Evrysdi patents expiration

33. Evzio patents expiration

34. Evzio (autoinjector) patents expiration

35. Exem Foam Kit patents expiration

36. Exkivity patents expiration

37. Fetroja patents expiration

38. Fintepla patents expiration

39. Firvanq Kit patents expiration

40. Genosyl patents expiration

41. Hetlioz patents expiration

42. Hetlioz Lq patents expiration

43. Illuccix patents expiration

44. Imbruvica patents expiration

45. Impoyz patents expiration

46. Inlyta patents expiration

47. Isturisa patents expiration

48. Jublia patents expiration

49. Jylamvo patents expiration

50. Kapspargo Sprinkle patents expiration

51. Kengreal patents expiration

52. Kimyrsa patents expiration

53. Lenvima patents expiration

54. Licart patents expiration

55. Lodoco patents expiration

56. Lokelma patents expiration

57. Lonhala Magnair Kit patents expiration

58. Mavyret patents expiration

59. Narcan patents expiration

60. Nityr patents expiration

61. Obredon patents expiration

62. Ojjaara patents expiration

63. Omlonti patents expiration

64. Ongentys patents expiration

65. Onpattro patents expiration

66. Opfolda patents expiration

67. Orbactiv patents expiration

68. Orladeyo patents expiration

69. Otiprio patents expiration

70. Oxbryta patents expiration

71. Oxlumo patents expiration

72. Pemazyre patents expiration

73. Pemetrexed patents expiration

74. Pemfexy patents expiration

Strength	Dosage	Availability
EQ 110MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP15746995A	2021-10-13	Bülle Dr., Jan	Granted and Under Opposition

Strength	Dosage	Availability
4.5MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
13.5MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 1GM/100ML BASE (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 100MG/10ML BASE (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 500MG/50ML BASE (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP15807916A	2022-10-26	STADA Arzneimittel AG	Granted and Under Opposition
EP15807916A	2022-10-21	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9463183	July, 2017	FWD Entered	Silvergate Pharmaceuticals, Inc.	KVK-Tech, Inc.

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription